BEAM — Beam Therapeutics Inc. stock price, charts and financials

QT42Beam Therapeutics Inc.

Beam Therapeutics Inc. (NASDAQ: BEAM) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
25.91
+0.39+1.53%
OverviewShort InterestFilings
BEAMQT42Beam Therapeutics Inc.·NASDAQ
25.91+1.53%
Earnings
Up 1.5% — Earnings due 2026-08-04 — pre-report positioning.
Medium confidence
TA
Loading chart...
Signal & projected range
Insider open-market saleHistorical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.
Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
KOD-4.21%$39.83ATAI+0.00%$7.18TRVI-1.92%$17.90TARS+3.86%$61.32CLDX-0.97%$37.69GPCR+0.67%$48.36RARE+0.44%$25.02NRIX+0.04%$23.22
Snapshot
Index-P/E-EPS (ttm)-0.68Insider Own14.22%Shs Outstand102.88MPerf Week1.67%
Market Cap2.63BForward P/E-EPS next Y-4.55Insider Trans-3.38%Shs Float87.94MPerf Month-23.78%
Enterprise Value2.59BPEG-EPS next Q-Inst Own-Short Float26.40%Perf Quarter-15.86%
Income-64.85MP/S16.01EPS this Y-543.24%Inst Trans-Short Ratio10.24Perf Half Y-12.87%
Sales164.01MP/B2.26EPS next Y-4.12%ROA-4.39%Short Interest23.22MPerf YTD-7.94%
Book/sh-P/C-EPS next 5Y-ROE-5.89%52W High38.85 -33.30%Perf Year26.65%
Cash/sh-P/FCF-EPS past 3/5Y-ROIC-26.15%52W Low15.84 63.59%Perf 3Y-20.52%
Dividend Est.-EV/EBITDA-Sales past 3/5Y31.91% -Gross Margin-39.17%Volatility5.26% 6.21%Perf 5Y-72.37%
Dividend TTM-EV/Sales15.78EPS Y/Y TTM85.15%Oper. Margin-226.58%ATR (14)1.88Perf 10Y-
Dividend Ex-DateNov 04, 2013Quick Ratio16.99Sales Y/Y TTM156.25%Profit Margin-39.66%RSI (14)35.90Recom2.37
Dividend Gr. 3/5Y-Current Ratio16.99EPS Q/Q26.61%SMA20-13.19%Beta2.21Target Price54.75
Payout0.00%Debt/Eq0.22Sales Q/Q357.14%SMA50-16.95%Rel Volume0.47Prev Close25.52
Employees522LT Debt/Eq0.23EarningsAug 04SMA200-9.19%Avg Volume2.25MPrice25.91
IPO DateFeb 06, 2020Option/ShortYes / YesEPS/Sales Surpr.11.46% 189.13%Net Debt/EBITDA1.17Volume1,067,706Change1.53%
Analyst Ratings
DateActionAnalystRatingTarget
May-21-26ReiteratedH.C. WainwrightBuy$80
May-13-26ReiteratedTudor Pickering$40 → $39
Feb-25-26ReiteratedRBC CapitalSector Perform$26
Feb-20-26InitiatedCanaccordBuy$74
Jan-21-26ReiteratedTudor Pickering$37 → $41
Jan-07-26ReiteratedUBS$28
Nov-24-25InitiatedEvercore ISIOutperform$35
Oct-09-25InitiatedJefferiesBuy$41
May-07-25ReiteratedGuggenheimBuy$55
Mar-28-25UpgradeB of A SecuritiesNeutral → Buy
Latest News
Today
Today06:03AM
Beam Therapeutics: A Valuation With Upside Leftseekingalpha.com
Jul-23-26
Jul-23-2607:02AM
Beam Therapeutics To Present Updated Clinical Data From Phase 1/2 Trial Evaluating BEAM-302 For Alpha-1 Antitrypsin Deficiency At ERS Congress 2026Benzinga
07:00AM
Beam Therapeutics to Present Updated Data from Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) in Late-Breaking Oral Presentation at the European Respiratory Society (ERS) Congress 2026globenewswire.com
02:15AM
Beam Therapeutics Inc. (NASDAQ:BEAM) Given Average Rating of “Moderate Buy” by Brokeragesdefenseworld.net
Jul-21-26
Jul-21-2603:14AM
Amova Asset Management Americas Inc. Has $91.16 Million Stock Holdings in Beam Therapeutics Inc. $BEAMdefenseworld.net
Jul-20-26
Jul-20-2601:30PM
Cathie Wood Is Buying This Up-and-Coming Biotech Stock. Should You Follow Her Lead?fool.com
Jul-16-26
Jul-16-2607:30AM
The Battle For Sickle CellSeekingAlpha
Jul-09-26
Jul-09-2610:22AM
Prime Medicine Beats Beam Therapeutics In Patent Dispute - But Both Are Investableseekingalpha.com
Jul-08-26
Jul-08-2601:29PM
Prime Medicine Secures Favorable Arbitration Ruling in Beam Therapeutics Casebenzinga.com
05:45AM
A New CRISPR "DNA Shredder" Could Change Gene-Editing -- What It Means for CRISPR Therapeuticsfool.com
Jul-07-26
Jul-07-2606:22AM
HC Wainwright & Co. Reiterates Buy on Beam Therapeutics, Maintains $80 Price TargetBenzinga
Jun-30-26
Jun-30-2609:03AM
Vertex Pharmaceuticals Has One Of The Widest And Most Durable Moats In BiotechSeekingAlpha
Jun-29-26
Jun-29-2610:35AM
Powder Keg Stocks: 10 Most‑Shorted Names Primed For A Monster Squeezebenzinga.com
Jun-26-26
Jun-26-2602:20PM
The Disinflation Trade Has A New Address: GenomicsSeekingAlpha
08:40AM
Beam Therapeutics: A Better Entry Point Is Likely Coming (Rating Downgrade)SeekingAlpha
Company

Beam Therapeutics Inc., founded in 2017 and based in Cambridge, Massachusetts, operates as a pioneering biopharmaceutical firm. Its core mission involves engineering precise genetic remedies to tackle a spectrum of severe human ailments, primarily within the United States. The company's developmental portfolio features several key candidates: BEAM-101 is being advanced to treat both sickle cell disease and beta thalassemia. BEAM-102 is specifically designed for addressing sickle cell disease. BEAM-201, an allogeneic chimeric antigen receptor T-cell therapy, is under investigation for individuals suffering from relapsed or refractory T-cell acute lymphoblastic leukemia. BEAM-301 is a liver-targeted candidate aimed at patients afflicted with Glycogen Storage Disease Type Ia. Beyond these flagship programs, Beam Therapeutics is also engaged in devising treatments for alpha-1 antitrypsin deficiency, various ocular conditions, and other disorders impacting the liver, muscular system, and central nervous system. To further its research and development objectives, Beam Therapeutics has forged numerous strategic alliances and partnerships. These include collaborations with Boston Children's Hospital; a research and clinical trial agreement with Magenta Therapeutics, Inc.; a licensing deal with Sana Biotechnology, Inc.; and a research partnership with the Institute of Molecular and Clinical Ophthalmology Basel. Additionally, the company maintains research collaborations with both Pfizer Inc. and Apellis Pharmaceuticals, Inc., alongside a comprehensive collaboration and license agreement with Verve Therapeutics, Inc.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue164140643786152000
Cost of Goods Sold Incl. D&A2292236803122321035534
Gross Profit-64117-304378-251-180-103-55-34
Selling, General and Administrative Excl. Other1151141121178857302112
Research and Development4164103684373123871035534
Other Operating Expense-223-23-3680-312-232-103-55-34
Operating Income-371-384-416-176-338-392-133-75-46
Interest Expense11440000000
Unusual Expense
—————————
Non-Operating Income (Expense)31734739455322-62-3-71
Net Income Before Taxes-65-80-377-131-286-371-195-78-117
Income Taxes000130000
Consolidated Net Income-65-80-377-133-289-371-195-78-115
Net Income From Continuing Operations-65-80-377-133-289-371-195-78-117
Net Income-65-80-377-133-289-371-195-78-115
EPS (Recurring)-0.64-0.81-4.58-1.72-4.13-5.77-5.49-1.53-3.28
EPS (Basic, Before Extraordinaries)-0.64-0.81-4.58-1.72-4.13-5.77-5.49-1.53-3.28
EPS (Diluted)-0.68-0.81-4.58-1.72-4.13-5.77-5.49-1.53-3.28
EBITDA-32-30-355-102-272-230-128-72-45
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio
—————————
Price To Sales Ratio16.2719.6031.785.5444.8898.08———
Gross Margin-39.0283.57-475.00100.00-411.48-346.15———
Operating Margin-226.22-274.29-650.00-46.56-554.10-753.85———
Net Margin-39.63-57.14-589.06-35.19-473.77-713.46———
Shares Outstanding1039982777064475135
Market Capitalization2,6692,7442,0342,0962,7385,1003,837——
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$41.23$34.05$26.88$19.70$12.52● Close Price0.00M2.95M5.90M8.85M11.80MUSD Trades VolumeAugSepOctNovDec2026FebMarAprMayJunJulAug
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Simon AmyChief Medical OfficerJul 27 '26Sale25.7416,667429,03785,696Jul 29
Simon AmyChief Medical OfficerJun 30 '26Sale34.7337312,954102,363Jul 02
Evans John M.CEOJun 30 '26Option Exercise1.0325,00025,7501,072,205Jul 01
Evans John M.CEOJun 30 '26Sale34.3125,000857,6851,047,205Jul 01
Evans John M.CEOJun 29 '26Sale35.4925,000887,3521,047,205Jul 01
Evans John M.CEOJun 29 '26Option Exercise0.7625,00019,0311,065,868Jul 01
FMR LLC10 percent owner, other: See Remark 1Jun 26 '26Sale35.26251,4888,867,467854,583Jun 29
FMR LLC10 percent owner, other: See Remark 1Jun 25 '26Sale35.1233,3721,172,0251,106,071Jun 29
Ciaramella GiuseppePresidentJun 17 '26Option Exercise0.9635,50534,228253,911Jun 22
Evans John M.CEOApr 01 '26Sale24.5830,078739,3171,047,205Apr 06
Simon AmyChief Medical OfficerApr 01 '26Sale24.586,700164,686102,735Apr 06
Cavanagh Bethany JSVP, Finance and TreasurerApr 01 '26Sale24.583,24279,68851,171Apr 06
Bellon ChristineChief Legal OfficerApr 01 '26Sale24.585,956146,398109,711Apr 06
Ciaramella GiuseppePresidentApr 01 '26Sale24.5811,810290,290218,406Apr 06
Evans John M.CEOMar 31 '26Option Exercise0.6725,00016,7501,011,667Apr 01
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.